Introduction
When searching for biologically active molecules, phenotypic screening is often the most straightforward and intuitive way to discover relevant hits. The alternative is target-based screening in which a large number of compounds are screened against a single target protein, and subsequently, the active hits can be further optimized through medicinal chemistry efforts [1] . However, according to a recent analysis of new molecular entities, target-based approaches are not as efficient as traditional phenotype-based methods in terms of generating first-inclass small-molecule drugs [2] . One of the major limitations of target-based strategies is the fact that many compounds are found to interact with multiple targets, with most drug molecules interacting with six known molecular targets on average [3] . Therefore the 'one drug, one target' paradigm, thought to be the cornerstone of target-based methods, often does not hold true for compounds identified using target-based methods. This deficiency has lead to a paradigm shift that, when coupled with recent technological advances in proteomics and genomics methods, has resulted in a renaissance for phenotype-based screening methods.
One of the major advantages of phenotype-based approaches is that they provide an unbiased way to find active compounds in the context of complex biological systems. Because phenotypic screening takes place in a physiologically relevant environment of cells or whole organism, the results from such screens provide a more direct view of the desired responses as well as highlight potential side effects. More importantly, phenotypic screens can lead to the identification of multiple proteins or pathways that may not have been previously linked to a given biological output. Therefore, identifying the molecular targets of active hits from phenotypic screens is a crucial process that is required to understand underlying mechanisms and to further optimize active compounds. Because target identification from phenotypic screens is expected to generate a spectrum of possible targets, the term 'target deconvolution' was coined to more accurately define the process.
Over the last decade, a number of technologies from a wide range of fields have been explored to identify targets from phenotypic screens. In particular, proteomics and genomics-based approaches have become more powerful when combined with whole genome sequencing [4] . High-throughput imaging platforms and computational analysis also have helped to find relevant pathways and proteins based on phenotype changes [5] . Recent advances in quantitative mass spectrometry techniques have facilitated quantitative analysis of proteins, and greatly enhanced the sensitivity of target detection [6] . In this review, we will focus on the most recent examples of target deconvolution techniques in modern phenotypic profiling.
affinity-based and activity-based probes that can be used to isolate targets and more recently, label-free techniques to directly identify small molecule binding proteins. Since, many reviews have covered the general principles of these approaches [6] [7] [8] [9] , we will focus only on the most recent examples of each technique.
Affinity chromatography
Affinity purification is the most widely used technique to isolate specific target proteins from a complex proteome (Figure 1a) . Small molecules identified in phenotypic screens are immobilized onto a solid support that can be used to isolate bound protein targets. This approach relies on extensive washing steps to remove non-binders, followed by specific methods to elute the proteins of interest. The eluted proteins can then either be directly identified using 'shotgun' type sequencing methods with multidimensional liquid chromatography or be further separated by gel electrophoresis and analyzed by mass spectrometry. The identified peptide sequences can then be used in database searches to identify the target protein [10] .
Although the idea is simple, immobilizing a small molecule onto a solid support is a challenging task. Any modification of the active molecules has the potential to affect binding affinity to the target, therefore the process requires substantial knowledge of structureactivity relationship and often requires significant chemistry efforts to identify a site for attachment of the affinity tag. Moreover, for some molecules, the addition of any kind of bulky tag leads to a dramatic loss of activity. In order to overcome these problems, a relatively small azide or an alkyne tag has been widely used to minimize structural perturbation and to conjugate an affinity tag via 'click chemistry' after the active hit is bound to its target (Figure 1b) [11] . Since the modified hits do not contain a bulky tag, which can interfere with membrane permeability, this method is particularly useful to search for intracellular targets and has been used, for example, for isolating targets of kinase inhibitors in mammalian cells [12, 13] .
In addition to an affinity tag, it is also possible to use a photoreactive group to induce covalent cross-linking and secure the interaction between a weakly bound small molecule and a protein target (Figure 1c ). For optimal identification, the hit compound needs to be modified with a small photoreactive group such as a benzophenone, diazirine, or arylazide, and also requires a reporter group Affinity chromatography. (a) An active hit is directly linked to a solid support or tagging group such as biotin, and its target protein isolated via affinity pull-down. The isolated proteins are further analyzed by mass spectrometry; (b) An active hit is modified with a small 'clickable' group for in situ labeling with minimal structural perturbation; (c) A photo-reactive group such as diazirine group is added to induce covalent cross-link between the hit compound and its target.
for rapid isolation. One interesting example is the case of imatinib, also known as Gleevec [14 ] . This drug was rationally designed to target the Bcr-Abl oncogenic receptor tyrosine kinase, and marketed as an anti-cancer drug. However, imatinib has been reported to reduce hypertension [15] and also reduce b-amyloid in the brain [16] . Recently, imatinib was labeled with an aryl azide and used to identify g-secretase activating protein (gSAP) as an additional molecular target [14 ] .
Since photo-affinity labeling requires a photo-reactive group and a reporter tag, 'all-in-one' functional groups containing both components have been introduced to minimize structural modification without using radioisotopes [17] . Alternatively, a multifunctional benzophenone-based small molecule library was also developed for integrated screening and target isolation [18 ] . This multifunctional scaffold can serve as a photoreactive group, a clickable tag and a protein-interacting functionality simultaneously. By embedding all three elements into one core scaffold, the process of phenotypic screening to target identification can be greatly accelerated.
In addition to effects from adding a tag for affinity purification, changing the composition of affinity beads can improve efficiency of purification by reducing falsepositives and boosting interaction between small molecules and protein targets [19 ,20] . For example, using high-performance magnetic beads can reduce multiple washing and separation steps to one procedure. These magnetic beads have been applied to identify the molecular target of thalidomide, a sedative used in the early 1960s that ended up having significant teratogenicity [19 ] . The drug is still used for leprosy and multiple myeloma, however, the reason for its link to birth defects was never understood due to the lack of suitable affinity Activity-based protein profiling. (a) Three main features of activity-based probes: a reactive electrophile that allows covalent attachment of the ABP in the active site of target enzyme, and enables rapid isolation and analysis of the target protein; a specificity region that directs the probe to the specific class of enzymes; and a tagging group for detection. (b) General workflow for using an ABP. When an active hit is identified from a screen it can be used to directly affinity isolate the target (top). Similarly, the direct screening of ABPs and covalent inhibitors in various systems such as cells and animals greatly facilitates the overall process of target deconvolution. Furthermore, broad-spectrum ABPs provide a powerful tool to study disease related pathways and class-wide enzyme assay platform.
probe. By using high-performance beads decorated with thalidomide, cereblon was identified as the molecular target.
Activity-based protein profiling
Activity-based probes (ABPs) are small molecule tools that can be used to monitor the activity of specific classes of enzymes. Over the past decade and a half, various ABPs have been designed to study proteases, hydrolases, phosphatases, histone deacetylases, and glycosidases [21-23], and these probes have proven to be valuable in investigating enzyme-related disease mechanisms including cancer [24] , microbial and parasitic pathogenesis [25, 26] , and metabolic disorders [27] . Typical activity-based protein profiling follows a similar overall workflow as affinity chromatography, including probe binding, protein separation, sequence analysis, and database searching ( Figure 2 ). However, because most ABPs are designed to target a specific enzyme class, ABPs are particularly useful for phenotypic screening and lead optimization where a specific enzyme or enzyme family is suspected to be involved in a certain disease state or pathway.
ABPs have three components; a reactive electrophile for covalent modification of enzyme active site, a linker or a specificity group for directing probes to specific enzymes, and a reporter or a tag for separating labeled enzymes (Figure 2a) . Therefore, a library of ABPs can be directly used for phenotypic screening and target identification simultaneously [28, 29] . In addition, covalent enzyme inhibitors can be readily converted to ABPs by attaching a tagging group, and the combined use of covalent inhibitors and ABPs in phenotypic screening greatly facilitates target identification and also offers a powerful tool to study function and mechanism of identified proteins [30, 31 ] . For example, Hall et al. successfully identified a small molecule that blocks the process of host cell invasion by the Toxoplasma gondii. The selected inhibitor, WRR-086 was then converted to an ABP by attaching an alkyne group for click chemistry, and used to identify TgDJ-1, a poorly characterized protein involved in oxidative stress response as a key player in host cell invasion [31 ] .
In order to covalently attach ABPs to target proteins, an active site nucleophile such as cysteine or serine is required. However, not all enzymes have a nucleophile in their active site. One way to overcome this problem is to incorporate a photo-reactive group, as has been demonstrated for probes of g-secretase [32] , metalloproteases [33] , and the proteasome [34] . Alternatively, an electrophile can be introduced to react with any cysteine residue in close proximity to the site of probe binding [35, 36] . Incorporating a clickable group such as an alkyne or an azide on an ABP can also facilitate a direct link from phenotypic screening to target identification [31 ,37,38] . In addition, to improve efficiency of two-step labeling, other tagging methods employing copper-free click chemistry [39] , sulfo-click chemistry [40] , Staudinger ligation [41] , or Diels-Alder reaction [42] were developed as an alternative to conventional click chemistry.
ABPs are not only useful for target identification, but also are powerful tools for the discovery of disease related proteins. For example, a cathepsin-C specific probe was used to show that dipeptidylpeptidase 1 (DPAP1) [29] plays a significant role in malarial infection and is potentially valuable drug target. In other examples, a broadspectrum probe was used to link several serine hydrolases including retinoblastoma-binding protein 9 (RBBP9) [43 ] , KIAA1363 [44] , and monoacylglycerol lipase (MAGL) [45] to cancer progression. Furthermore, the broad-spectrum ABPs used for target validation are also useful to set up class-wide enzyme assays to identify new inhibitors or to test existing library of small molecules in phenotypic screening [28, 46, 47, 48 ].
Label-free techniques
Label-free techniques have the advantage in that they do not require any chemical modification of an active compound, which can greatly facilitate the target identification process. This relatively new type of target identification strategy relies on changes in thermodynamic stability as the result of a protein-drug interaction. These methods are based on the concept that a protein has conformational flexibility in solution, making it more susceptible to proteolysis, however, once it binds to a small molecule, the overall complex will be more resistant to proteolysis [49] . One such label-free technique called DARTS (drug affinity responsive target stability) was used to successfully identify cellular targets of Rapamycin, FK506, didemnin B, and resveratrol [50] . Similarly, a 'pulse proteolysis' technique demonstrated that ligand bound proteins are more stable upon protein denaturation and proteolysis compared to the samples without a ligand (Figure 3a ) [51] .
Another technique termed SPROX (stability of proteins from rates of oxidation) is a quantitative mass spectrometry-based approach that, like DARTS, utilizes thermodynamic stability of ligand-protein complexes but focuses on changes in stability under oxidative conditions ( Figure 3b ) [52] . This method utilizes an oxidizing agent (H 2 O 2 ) in the presence of increasing concentration of a chemical denaturant to oxidize methionine residues in target proteins. After quenching the oxidation reaction, the amount of non-oxidized and oxidized methionine-containing peptides in each sample are quantified and plotted against concentrations of denaturant. Ligand bound proteins will show bigger shifts toward high-concentrations of denaturant compared to non-binders. Two cyclosporine A binding proteins were identified from a yeast proteome as a proof-of-principle study [53] , and previously unknown target proteins of resveratrol were later identified [54 ] .
Unlike DARTS and pulse proteolysis, which require gel electrophoresis to separate proteolysis-resistant complexes, SPROX measures concentrations of trypsinized peptides from a complex mixture by using a tandem LC-MS/MS technique such as MudPIT. Hence, SPROX has the potential to be used for more direct global analysis of drug-protein interactions.
Expression cloning techniques
Expression cloning techniques utilize a library of cDNAs inserted into cloning vectors to express a library of proteins. A small molecule-protein interaction can be detected by adding a tagged small molecule followed by affinity purification. In a sense, expression cloning techniques are similar to typical affinity purification because they also require chemical modification to attach a tag. However, when the target of interest is of low abundance or is unstable, expression cloning can be an excellent alternative.
One method to express a large-scale library of proteins is phage display (Figure 4a ). Phage display is an affinity selection technique initially developed to identify antigen-antibody interactions and protein-protein interactions. A library of DNA sequences can be fused to a gene encoding a phage coat protein. Hence, the phage will display one unique protein on its surface per phage particle. Phage particles that bind to a small molecule target with high affinity can be isolated. The isolated phage can be used for subsequent rounds of selection that can lead to further enrichment. Although, traditional phage display techniques have identified molecular targets of many natural and synthetic ligands [55] [56] [57] , more improved techniques have facilitated the process. In a recent example, Van Dorst et al. demonstrated that lytic (T7) cDNA phage display can be used as a fast, cost effective alternative to conventional filamentous phage (M13) display, and identified molecular targets of 17b estradiol [58] .
As an alternative to phage, mRNA display was introduced as a method in which proteins could be expressed as a fusion to their corresponding mRNAs (Figure 4b ) [59] . This allows direct affinity screening and rapid identification of the target protein by sequencing of the corresponding cDNA tag. However, since the initial proof-of-concept experiment a decade ago [60] , few actual examples of target identification have been reported. Most examples of mRNA display applications have been focused on protein-protein interaction and lead discovery.
Another alternative display method is the yeast threehybrid screen (Figure 4c ). This is an adaptation of the commonly used two-hybrid system for identification of protein-protein interactions. The three-hybrid system makes use of the same elements but includes a 'chemical dimerizer' that is used to link the small molecule of interest to the bait protein so that interaction with the prey domain can be measured. Although the idea was introduced nearly two decades ago [61] , there have been only a few reports using three-hybrid system for target identification of small molecules [62] . Recently, Chidley et al. incorporated a SNAP-tag to covalently label drug Label-free techniques for target deconvolution. (a) Limited proteolysis techniques such as DARTS and pulse proteolysis utilize stability of proteinligand complex under proteolytic condition. Ligand bound proteins are more resistant to proteolysis in the presence of denaturant (pulse-proteolysis) or without denaturant (DARTS), and non-binding proteins are hydrolyzed to small peptides and amino acids. All proteolysis resistant proteins can be analyzed by SDS-PAGE and identified by mass spectrometry; (b) SPROX technique is based on a similar principle, however, it exploits protein-ligand interaction under oxidative conditions in various concentrations of denaturant. Ligand bound proteins are more resistant to oxidant, thus requiring higher amounts of denaturant to generate the same degree of oxidation compared to non-binders. These results can be plotted and protein-ligand interactions result in a right shift of the plot. molecules inside yeast and were able to identify previously unknown targets for clinically approved drugs [63 ] .
In silico approach
Computer aided drug design is a major workhorse of target-based drug discovery. On the basis of docking studies and virtual screening, drug candidates with optimal potency and selectivity can be predicted. With the recent renaissance of phenotype-based drug discovery, these in silico technologies have found an important new role in the process of target prediction. Over the last two decades, extensive information regarding activity, structures and targets of small molecule libraries has been deposited into public databases such as ChEMBL [64] , DrugBank [65] and ChemBank [66] . There are also public web services such as TarFisDock [67] and SEA (Similarity Ensemble Approach) for target prediction of small molecules [68, 69 ] . Using these tools, targets of active compounds can be predicted based on similarities in structure between an active hit and well-characterized drugs in these databases. This computer aided target prediction has been widely used to identify new targets of known drugs [69 ,70 ] , to predict the targets of active hits from a library screening [71] [72] [73] , and to investigate the mechanism of action of hits discovered from phenotypic screens [74, 75] . For example, Lounkine et al. used a public database ChEMBL, and performed a large-scale 'ligand-based similarity search' to predict target proteins, which lead to the identification of 73 unintended off targets of 656 marketed drugs [69 ] . Additionally, recent advances in high-content screening platforms using automated imaging systems enable the establishment of phenotypic-SAR thus improving confidence levels in target prediction and providing important information regarding drug mode of action [76, 77] .
Conclusion and perspective
Small molecules have long been used as tools to manipulate biological systems. In addition to acting as therapeutic agents where the primary focus is on ultimate effects rendered by treatment with the compounds, small Expression cloning techniques. Proteins can be expressed using cloning vectors containing cDNA library, and these proteins exposed to small molecules for affinity selection. (a) Phage display: small molecule captured phage particles can be selectively eluted and transfected into bacterial cells for further amplification and enrichment. (b) mRNA display: mRNA display utilizes an in vitro translation system to generate a library of mRNA-protein fusions, and this newly generated library can be exposed to an immobilized small molecule. After affinity selection, the cDNA of the captured proteins can be amplified by PCR and used to identify the target or for a next round of selection for further enrichment. (c) Yeast three-hybrid screen: the screen construct of a bait domain containing a DNA binding domain fused to a protein of interest, and a prey domain containing a transcriptional activator for a reporter gene linked to a library of proteins encoded by a cDNA library. When the bait and prey domains interact through the small molecule dimerizer, transcription of a reporter gene is activated.
molecules also have the potential to function as reagents that allow detailed studies of the functional roles of diverse target proteins. History has proven that it is relatively simple to find small molecules that have a given biological effect on a cell or organism, however, the process by which the mechanism of action of the compound can be identified on a molecular level remains a major challenge. This is largely due to the fact that most small molecules do not simply bind to one target. Therefore, finding ways to deconvolute the list of possible players is of utmost importance. In this review, we have outlined some of the more recent advances in methods that can be used to link specific small molecules identified in a phenotypic screen to a valid target. You may have noticed that the list of recent examples where a given technique has been used to identify novel targets is somewhat short, especially given the rapid growth in the use of phenotypic screening methods over the past decade. We believe this is due to significant challenges that still exist in globally mapping out small molecule-target interactions. However, we also believe that rapid advances in analytical methods such as mass spectrometry coupled with advances in genetic methods and genomewide sequencing are likely to have a big impact on our ability to more rapidly and efficiently identify targets and furthermore to provide direct causal links between a hit binding to its target and a phenotypic outcome. We therefore feel the future is bright for phenotypic screening and future reviews on this topic are likely to have increasingly more concrete examples of how the techniques presented here have been applied in basic biology and drug discovery research.
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